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2

METHOD AND SYSTEM FOR
NON - INVASIVE BLOOD GLUCOSE

Malchoff, and G. Abbott, Diabetes Technology & Therapeu
tics , 7 (4 ) 2005 , 612-619 ) , people with diabetes would per
form SMBG more frequently and have improved quality of
life with aa non - invasive blood glucose monitoring device .
Currently, there remains a concentrated effort in academia
and industry to develop reliable , affordable non - invasive
blood glucose monitors. One technique of non - invasive
blood chemicals detection involves collecting and analyzing
light spectra data . Extracting information about blood char
acteristics such as glucose concentration from spectral or
other data obtained from spectroscopy is a complex problem
due to the presence of components ( e.g. , skin , fat, muscle,

MEASUREMENT USING SIGNAL CHANGE
OF THE NON -GLUCOSE COMPONENTS
INDUCED BY THE PRESENCE OF
GLUCOSE

5

CROSS - REFERENCE TO RELATED
APPLICATION
10

This patent application is a continuation of the co -pending
U.S. patent application Ser. No. 12 /407,999 , published as
U.S. Patent Application Publication No. 2009/0247843 , filed
on Mar. 20 , 2009 , titled “ Method and System for Non
Invasive
Blood Glucose Detection Utilizing Spectral Data of
One or More Components Other Than Glucose , " which
claims priority to U.S. Provisional Patent Application Ser.
No. 61 / 039,170 filed Mar. 25 , 2008 , the disclosure of which
is incorporated herein by reference .
BACKGROUND OF THE INVENTION

bone , interstitial fluid ) other than blood in the area that is

15 being
sensed. Such other components can influence these
signals in such a way as to alter the reading. In particular, the

resulting signal may be much larger in magnitude than the
limits the ability to accurately extract blood characteristics
20 information .
The prevailing view is to correlate the change in optical
portion of the signal that corresponds to blood and therefore

absorption at certain wavelengths with blood glucose con
Diabetes is a chronic disease that, when not controlled, centration , while igr
the fact that similar changes in
over time leads to serious damage to many of the body's optical absorption could also be caused by other factors,
systems , including the nerves, blood vessels , eyes , kidneys 25 such as physical exercise, medication , emotion , or a change
and heart. The National Institute of Diabetes and Digestive in body chemistry, such as endocrine levels, etc. As such ,
and Kidney Diseases (NIDDK) estimates that 23.6 million good correlations obtained in well controlled laboratory
people or 7.8 percent of the population in the United States conditions do not translate into successful, reliable market
have diabetes in 2007. Globally, the World Health Organi- devices.
zation (WHO ) estimates that more than 180 million people 30 The present invention is directed to overcoming one or
have diabetes, a number they expect to increase to 366 more of the problems set forth above .
million by 2030 , with 30.3 million in the United States.
According to the WH an estimated 1.1 million people died
SUMMARY OF INVENTION
from diabetes in 2005. They project that diabetes deaths will
increase by more than 50% between 2006 and 2015 overall 35 Embodiments of the present invention relate to a method
and by more than 80 % in upper -middle income countries. for detecting glucose in a biological sample. The method
The economic burden from diabetes for individuals and includes illuminating a biological sample with a light
society as a whole is substantial. According to the American source , collecting transmitted , transflected or reflected light
Diabetes Association , the total annual economic cost of from the sample, generating spectral data of one or more
diabetes was estimated to be $ 174 billion in the United 40 components in the sample other than glucose and analyzing
States in 2007. This is an increase of $ 42 billion since 2002 .
the spectral data of the one or more components sufficient to
This 32 % increase means the dollar amount has risen over
provide a glucose concentration measurement from the
$ 8 billion more each year.
spectral data of the one or more components other than
A vital element of diabetes management is the self- glucose .
monitoring of blood glucose ( SMBG) concentration by 45 These are merely some of the innumerable aspects of the
diabetics in the home environment. By testing blood glucose present invention and should not be deemed an all - inclusive
levels often, diabetics can better manage medication , diet listing of the innumerable aspects associated with the pres
and exercise to maintain control and prevent the long -term ent invention .
negative health outcomes . In fact, the Diabetes Control and
Complications Trial (DCCT ) , which followed 1,441 diabet- 50
BRIEF DESCRIPTION OF THE DRAWINGS
ics for several years , showed that those following an inten
sive - control program with multiple blood sugar tests each
For a better understanding of the present invention, ref
day as compared with the standard - treatment group had only erence may be made to accompanying drawings, in which :
one - fourth as many people develop diabetic eye disease ,
FIG . 1 illustrates a block flow diagram of aa method for

one - half as many develop kidney disease , one -third as many 55 detecting glucose in a biological sample, according to some
develop nerve disease , and far fewer people who already had embodiments;
early forms of these three complications got worse .
FIGS . 2A and 2B illustrate plots of a pulse wave corre
However, current monitoring techniques discourage regu- sponding to light absorption of arterial blood in a human

lar use due to the inconvenient and painful nature of drawing finger, according to some embodiments ;
blood through the skin prior to analysis, which causes many 60 FIG . 3 illustrates a graphical view of a water absorbance

diabetics to not be as diligent as they should be for good spectrum , according to some embodiments;
blood glucose control. As a result, non - invasive measureFIG . 4 illustrates a graphical view of an absorbance
ment of glucose concentration is a? desirable and beneficial spectrum of a 1250 mg/dL glucose solution, according to
development for the management of diabetes. A non - inva- some embodiments ;
sive monitor will make testing multiple times each day 65 FIG . 5 illustrates a graphical view of an absorbance
pain - free and more palatable for children with diabetes. spectrum of a 2500 mg/dL glucose solution, according to
According to a study published in 2005 (J. Wagner, C. some embodiments ;
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FIG . 6 illustrates a graphical view of differential water
spectrum , according to some embodiments; and
FIG . 7 illustrates a system for detecting glucose in a
biological sample, according to some embodiments .

The light may be collected by one or more detectors or
light-sensing devices. An array of photodiodes may be
utilized , for example .
Spectral data of one or more components in the sample
other than glucose may be generated < 106 > . The detector
may generate a corresponding current signal that is propor
tional to the power of the light received by the detector. The
current signal generated by the detector can be converted to
another form of signal , such as an analog voltage signal or
a digital signal. Such signals may be converted to spectral or
absorbance data using known processors and algorithms .
The spectral data of the one or more components may be
analyzed < 108 > , sufficient to provide a glucose concentra
tion measurement from the spectral data of the one or more
components other than glucose .
Spectroscopic data generation < 106 > and analysis < 108 >
may be carried out using a pulsatile or a stationary meth
odology.
A pulsatile data generation and analysis methodology has
been described in presently owned U.S. patent application
Ser. No. 12 /245,298 , filed Oct. 3 , 2008 , which is incorpo
rated herein by reference and U.S. patent application Ser.
No. 12/ 209,807 , filed Sep. 12 , 2008 , which is incorporated
herein by reference. When light is transmitted through a
biological sample, such as a human finger, the light is
absorbed and scattered by various components of the finger
including muscle, bone, fat and blood . It has been observed,
however, that light absorption by a human finger exhibits a
small cyclic pattern that corresponds to a heartbeat.
FIG . 2A depicts a plot 202 of a pulse wave that corre
sponds to the light absorption of arterial blood in the
capillary due to the heartbeat of the user . Although the
magnitude of the cyclic pattern is small in comparison to the
total photocurrent generated by the detector, considerable
information
be extracted
fromthatthethecyclic
patternheartofrate
the
plot
202. Forcan
example
, assuming
person's
is sixty beats per minute , the time between the start of any
pulse beat and the end of that pulse beat is one second .
During this one - second period, the plot will have a maxi
mum or peak 204 reading and minimum or valley 206
reading. The peak 204 reading of the plot corresponds to
when there is a minimum amount of blood in the capillaries,
and the valley 206 reading corresponds to when there is a
maximum amount of blood in the capillaries. By using
optical information provided by the peak and valley of the
cyclic plot , the major constituents that are in the body that
are not in the capillaries, such as fat, muscle (i.e. , protein)
and interstitial fluid , are excluded . These major constituents
that are not in the capillaries are excluded because they are
not likely to change during the one - second interval . In other
words, the light that is impeded by the blood can be detected
based on the peaks and valleys of the plot 202. FIG . 2A
illustrates the cyclic pattern on a magnified scale . FIG . 2B
depicts a more accurate reflection of the cyclic pattern in
terms of signal amplitude .
In a stationary data acquisition and analysis methodology,
the light absorption is averaged over a period of time to
remove the fluctuation in light absorption due to the heart
beat . The glucose concentration can be extracted from the
averaged light absorption at different wavelengths over the
same period of data acquisition time .
Referring again to FIG . 1 , analyzing < 108 > may also
include mathematically comparing the changes in absor
bance of the one or more components to changes in glucose
concentration . Analyzing < 108 > may include eliminating
spectral data of the one or more components for changes in

5

DETAILED DESCRIPTION OF THE
INVENTION

In the following detailed description, numerous exem
plary specific details are set forth in order to provide a 10
thorough understanding of the invention . However, it will be
understood by those skilled in the art that the present
invention may be practiced without these specific details, or
with various modifications of the details. In other instances , 15
well known methods, procedures, and components have not
been described in detail so as not to obscure the present
invention .

Embodiments of the invention relate to a method for

non - invasiveweakblood
Glucose
has 20
extremely
opticalglucose
absorptiondetection
in the .visible
( Vis ) and
near infrared (NIR ) regions from about 400 nm to about
2500 nm . It is very difficult to accurately determine the
concentration of glucose in a biological sample by determining the portion of optical absorption generated by glu- 25
cose in the biological sample, because the portion of optical
absorption by other components is typically several orders
of magnitude larger than that directly by glucose in the two
wavelength regions. But , glucose can induce changes in the
optical absorption of other components in the sample, such 30
as hemoglobin or water. These changes in optical absorption
of components other than glucose can be used to indirectly
determine the concentration of glucose in a biological
sample.
Referring to FIG. 1 , a block flow diagram of a method for
detecting glucose in a biological sample is shown , according
to some embodiments and is generally indicated by numeral
100. In the description of the flowcharts, the functional

35

explanation marked with numerals in angle brackets < nnn >, 40

will refer to the flowchart blocks bearing that numeral. A
biological sample may be illuminated with a light source
< 102 > . Transmitted , transflected or reflected light may then
be collected from the sample < 104 > . Spectral data of one or
more components in the sample other than glucose may be
generated < 106 > . The spectral data of the one or more
components may be analyzed , sufficient to provide a glucose
concentration measurement from the spectral data of the one
or more components other than glucose < 108 > .
Illuminating < 102 > may refer to exposing the biological
sample to a light source in the visible (Vis ), near infrared
(NIR) or mid -infrared spectral regions. The wavelength
range for illumination < 102 > may occur between about 400
nm and about 10,000 nm , for example . The illuminating
< 102 > may occur between about 400 nm and about 2500 nm
or about 400 nm and about 1000 nm , for example . The light
source may be lasers , light emitting diodes (LED ) , incandescent lamps, halogen lamps or a combination thereof, for
example . The light source may be a plurality of lasers . Prior
to or after illumination of the sample < 102>, a reference
sample may be illuminated for calibration .
The biological sample may be any portion of the human
body that contains glucose or has the potential to contain
glucose . The biological sample may be a human finger, toe ,
ear lobe , tongue or arm , for example.
After illumination < 102 > , transmitted, transflected or
reflected light may then be collected from the sample < 104 > .

45

50

55

60
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absorbance not related to interactions with glucose .
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Because glucose in the biological sample has such a weak foregoing description , certain aspects of the present inven
optical signal in the Vis and NIR spectral range, the methods tion are not limited by the particular details of the examples
of the present invention do not attempt to analyze the illustrated herein , and it is therefore contemplated that other
glucose signal. Glucose does physically or chemically inter- modifications and applications, or equivalents thereof will
act with one or more components in the blood and induce 5 occur to those skilled in the art. The terms “ have ,” “ having, "
changes in the optical signal of these components as a “ includes ” and “ including ” and similar terms as used in the
function of glucose concentration . By analyzing the changes foregoing specification are used in the sense of “ optional” or
in the one or more components, the concentration of glucose “ may include ” and not as “ required .” Many changes, modi
fications, variations and other uses and applications of the
in the sample may be determined .
10 present construction will , however, become apparent to
EXAMPLE
those skilled in the art after considering the specification and
the accompanying drawings. All such changes, modifica
FIG . 3 shows the NIR spectrum of water between 850 am tions , variations and other uses and applications which do
to 1100 nm . A strong positive peak is seen between about not depart from the spirit and scope of the invention are
920 nm and 1070 nm . The spectrum was taken with a 15 deemed to be covered by the invention which is limited only
Perkin - ElmerTM Lambda - 14TM Double Beam UV - Vis -NIR by the claims that follow .
( 190 nm to 1100 nm ) spectrometer. The scanning speed was
a

30 nm /min , the spectrum resolution was 4 nm , and one data
The invention claimed is :
point was collected per nm . The reference was the air and the
1. A method for measuring a blood glucose concentration
sample was HPLC grade water in a quartz cuvette with 1 cm 20 comprising:
light path . The baseline absorbance of the spectrum , about
a ) illuminating a biological sample with a light beam from
0.05 , is due to reflections from two air / quartz interfaces and
a light generating device ; and
b ) receiving and analyzing an induced change of a light
two water /quartz interfaces.
FIG . 4 shows the absorbance spectrum of a 1250 mg /dL
signal of one or more non - blood glucose components
solution of alfa - D ( + ) - glucose in HPLC grade water, and 25
from the sample with a detector,
FIG . 5 shows the absorbance spectrum a 2500 mg/ dL
wherein the induced change of the light signal is caused
solution of alfa - D ( + ) - glucose in HPLC grade water. The two
by physical or chemical interaction of glucose with the
one or more non- blood glucose components;
spectra were taken under the same condition as the water

spectrum in FIG . 3 , except that the quartz cuvette containing
HPLC grade water was used as the reference. To minimize 30
the effect of temperature on water absorption , the two
glucose solutions and HPLC grade water were equilibrated
in the sample chamber of the spectrometer for four hours
Both FIG . 4 and FIG . 5 show a large negative peak at 35
about 960 nm , about -0.0018 for the 1250 mg /dL glucose
solution and about -0.0030 for the 2500 mg/dL glucose

before the measurements .

wherein the analyzing of the induced change of the light
signal comprises:
generating spectral data , having peaks and valleys, of
the one or more non -blood glucose components ;
analyzing spectral data of the one or more blood
components, wherein the one or more blood com
ponents are non- blood glucose , to provide a blood
glucose measurement by measuring light absorption
based on peaks and the valleys of the spectral data ,

solution . This negative peak is not caused by the optical
which excludes an interference of a measurement by
absorption of glucose in this region. Instead , it is aa result of
fat, muscle, and interstitial fluid , without analyzing a
change in water absorption due to the presence of glucose . 40
glucose signal,
This is supported by the simulated differential water specwherein the light absorption measured of the one or
more non -blood glucose components contains a
trum in FIG . 6. The simulated differential water spectrum
change of an absorption amount that is induced by an
was obtained by manually red shifting 1 nm of all data points
in the water spectrum of FIG . 3 , then subtracting the original
amount of a presence of the blood glucose which is
water spectrum from the red shifted spectrum . FIG . 6 shows 45
used to indirectly determine the concentration of the
blood glucose.
a negative peak centered at 960 nm with a very similar peak
shape as those of FIG . 4 and FIG . 5 .
2. The method of claim 1 , wherein the light generating
FIG . 7 shows an exemplary system for conducting an device comprises a Laser, a light emitting diode ( LED ) , an
embodiment of the present invention that is generally indi- incandescent lamp, a halogen lamp or a combination thereof.
cated by numeral 700. The system of FIG . 7 comprises a 50 3. The method of claim 1 , further comprising eliminating

light source 701 , biological sample 703 , detector 705 , and light signal data of the one or more non - blood glucose
spectral data analysis device 707. A light source 701 may be components for changes in absorbance not related to inter
lasers, light emitting diodes ( LED ) , incandescent lamps, actions with the glucose .
halogen lamps or a combination thereof, for example . The
4. The method of claim 1 , further comprising forming a
light source may be a plurality of lasers . A biological sample 55 Visible or NIR spectra using the light signal.
703 may be a human finger, toe , car lobe , tongue or arm . A
5. A blood glucose concentration measuring device com
detector 705 may be any of a wide variety of light detectors
prising:
with an illustrative, but nonlimiting, example being an array
a ) a light generating device configured to illuminate a
of photodiodes. Spectral data analysis device 707 may be
biological sample with a light beam ; and

any device capable of analyzing spectral data as described 60 b ) a programmable computing device comprising light
herein . An illustrative, but nonlimiting, example of a specphotocurrent sensors configured to receive and analyze
tral data analysis device 707 may include an SR760TM from
an induced change of a light signal of one or more
Stanford Research Systems, which is a single -channel 100
kHz FFT spectrum analyzers with a dynamic range of 90 dB
and a real- time bandwidth of 100 kHz.
Thus, there has been shown and described several

embodiments of a novel invention . As is evident from the

65

non - blood glucose components from the sample with a
detector,
wherein the induced change of the light signal is caused
by the physical or chemical interaction of glucose with
the one or more non -blood glucose components;
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wherein the programmable computing device analyzes
the induced change of the light signal by :
generating spectral data, having peaks and valleys , of
the one or more non - blood glucose components;
analyzing spectral data of the one or more blood 5
components, wherein the one or more blood com
ponents are non - blood glucose , to provide a blood
glucose measurement by measuring light absorp
tion based on peaks and the valleys of the spectral 10
data , which excludes an interference of a mea
surement by fat, muscle, and interstitial fluid ,
without analyzing a glucose signal ,
wherein the light absorption measured of the one or
more non -blood glucose components contains a
change of an absorption amount that is induced by 15
an amount of a presence of the blood glucose
which is used to indirectly determine the concen
tration of the blood glucose .
6. The device of claim 5 , wherein the light generating
device comprises a Laser, a light emitting diode (LED ), an 20
incandescent lamp, a halogen lamp or a combination thereof.
7. The device of claim 5 , wherein the programmable

computing device is configured to eliminate the light signal
data of the one or more non - blood glucose components for

c ) a computing device configured to
generate spectral data , having peaks and valleys, of the
one or more non- blood glucose components;
analyze spectral data of the one or more blood compo
nents, wherein the one or more blood components are
non - blood glucose , to provide a blood glucose mea

surement by measuring light absorption based on peaks
and the valleys of the spectral data, which excludes an
interference of a measurement by fat, muscle , and
interstitial fluid , without analyzing a glucose signal,
wherein the light absorption measured of the one or more
non - blood glucose components contains a change of an
absorption amount that is induced by an amount of a
presence of the blood glucose which is used to indi
rectly determine the concentration of the blood glucose .
10. The system of claim 9 , wherein the light generating
device comprises lasers, light emitting diodes, halogen
lamps, incandescent lamps or a combination thereof.
11. The system of claim 9 , wherein the light generating
device
configured
lightlight
in atregions
least .one of near
infraredis, mid
- infraredtoandemit
visible
12. The system of claim 9 , wherein the light generating

device is configured to emit light having a wavelength in a

range of 400 nm to 2500 nm .

13. The system of claim 9 , wherein the computing device
changes in absorbance not related to interactions with the 25 is configured
to mathematically compare changes in absor
glucose .
2

8. The device of claim 5 , wherein the programmable

bance of the one or more blood components to changes in
blood glucose concentration .

spectra using the light signal .
9. A system for detecting blood glucose in a biological
sample, comprising:
a) a light generating device configured to illuminate a
biological sample comprising a plurality of blood com

30 isareconfigured
to eliminate portions of the spectral data that
attributable to changes in absorbance not related to

computing device is configured to form a Visible or NIR

ponents ;

14. The system of claim 9 , wherein the computing device
9

interactions with blood glucose .
15. The system of claim 9 , wherein the biological sample
comprises a portion of at least one of a human finger, toe , ear

b) a detector configured to collect transmitted , transflected 35 lobe, tongue or arm .
or reflected light from the biological sample; and
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